Fungal Infections in COVID-19 Intensive Care Patients.
COVID-19
fungal infections
intensive care
Journal
Polish journal of microbiology
ISSN: 2544-4646
Titre abrégé: Pol J Microbiol
Pays: Poland
ID NLM: 101229003
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
24
06
2021
revised:
05
08
2021
accepted:
09
08
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
8
10
2021
Statut:
ppublish
Résumé
Opportunistic fungal infections increase morbidity and mortality in COVID-19 patients monitored in intensive care units (ICU). As patients' hospitalization days in the ICU and intubation period increase, opportunistic infections also increase, which prolongs hospital stay days and elevates costs. The study aimed to describe the profile of fungal infections and identify the risk factors associated with mortality in COVID-19 intensive care patients. The records of 627 patients hospitalized in ICU with the diagnosis of COVID-19 were investigated from electronic health records and hospitalization files. The demographic characteristics (age, gender), the number of ICU hospitalization days and mortality rates, APACHE II scores, accompanying diseases, antibiotic-steroid treatments taken during hospitalization, and microbiological results (blood, urine, tracheal aspirate samples) of the patients were recorded. Opportunistic fungal infection was detected in 32 patients (5.10%) of 627 patients monitored in ICU with a COVID-19 diagnosis. The average APACHE II score of the patients was 28 ± 6. While 25 of the patients (78.12%) died, seven (21.87%) were discharged from the ICU.
Identifiants
pubmed: 34584533
doi: 10.33073/pjm-2021-039
pmc: PMC8459001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-400Informations de copyright
© 2021 Ayşenur Sümer Coşkun and Şenay Öztürk Durmaz.
Déclaration de conflit d'intérêts
Conflict of interest The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.
Références
Clin Infect Dis. 2020 Oct 18;:
pubmed: 33070173
Jpn J Infect Dis. 2021 Jul 21;74(4):307-315
pubmed: 33390434
J Infect. 2009 Nov;59(5):360-5
pubmed: 19744519
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Scand J Infect Dis. 2004;36(11-12):860-4
pubmed: 15764174
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
pubmed: 16127033
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Clin Infect Dis. 2020 Oct 30;:
pubmed: 33124650
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
J Antimicrob Chemother. 2007 Sep;60(3):459-60
pubmed: 17646200
Mycoses. 2021 Feb;64(2):152-156
pubmed: 33275821
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Clin Infect Dis. 2003 Nov 1;37(9):1172-7
pubmed: 14557960
Eur J Clin Microbiol Infect Dis. 2006 Jul;25(7):419-25
pubmed: 16773391
Med Mycol. 2021 Jan 4;59(1):110-114
pubmed: 32914189
Front Microbiol. 2020 Nov 19;11:591452
pubmed: 33329471
Clin Infect Dis. 2005 Nov 1;41(9):1232-9
pubmed: 16206095
J Infect. 2021 Feb;82(2):e45-e46
pubmed: 32771402
J Fungi (Basel). 2021 May 31;7(6):
pubmed: 34073125
Mycoses. 2021 Feb;64(2):144-151
pubmed: 33217071
J Antimicrob Chemother. 2020 Nov 1;75(11):3386-3390
pubmed: 32766706
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
J Fungi (Basel). 2017 Jul 19;3(3):
pubmed: 29371558